Get the Stockscreener App
263.38
0.84%
2.19
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $263.38, with a volume of 11.23M.
It is up +0.84% in the last 24 hours and down -8.51% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$261.19
Open:
$269
24h Volume:
11.23M
Relative Volume:
3.77
Market Cap:
$141.58B
Revenue:
$32.53B
Net Income/Loss:
$4.23B
P/E Ratio:
18.72
EPS:
14.07
Net Cash Flow:
$6.28B
1W Performance:
-2.68%
1M Performance:
-8.51%
6M Performance:
-15.01%
1Y Performance:
-4.29%
1-Day Range:
$262.21
$269.61
1-Week Range:
$253.30
$272.69
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
263.38 | 141.58B | 32.53B | 4.23B | 6.28B | 7.81 |
|
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. stock rises Friday, still underperforms market - MarketWatch
What's Going On With Amgen Stock On Friday? - Benzinga
Amgen (AMGN) Rises Over 3% Amid Novo Nordisk Trial Results - GuruFocus.com
Amgen (NASDAQ:AMGN) Shares Gap UpTime to Buy? - MarketBeat
Principal Financial Group Inc. Purchases 35,785 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Amgen (NASDAQ:AMGN) Reaches New 1-Year LowTime to Sell? - MarketBeat
Amgen stock touches 52-week low at $257.77 amid market shifts By Investing.com - Investing.com South Africa
Amgen stock touches 52-week low at $257.77 amid market shifts - Investing.com Australia
Why Is Amgen Inc. (AMGN) Among the Best Dividend Stocks to Invest In? - Insider Monkey
Herceptin Biosimilar Market Future Business Opportunities - openPR
Amgen's SWOT analysis: stock poised for growth amid obesity market potential - Investing.com
Amgen Hit With $50M Infringement Verdict Over Leukemia Drug - Law360
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen hit with $50.3 mln US verdict in cancer drug patent lawsuit - Reuters
Amgen Owes Lindis $50 Million Patent Royalty Over Blincyto (1) - Bloomberg Law
Amgen (NASDAQ:AMGN) Stock Rating Lowered by StockNews.com - MarketBeat
Biologics Market to See Booming Growth 2024-2031 | AbbVie Inc., - openPR
Amgen (AMGN) Stock Moves -0.21%: What You Should Know - Yahoo Finance
Amgen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Amgen Inc. (AMGN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
KRAS Inhibitors Market Top Companies StudyAmgen, Boehringer - openPR
Viridian taking on Amgen in TED market - BioCentury
Viridian Continues Building Case For Veligrotug In TED - Citeline News & Insights
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - Yahoo! Voices
Amgen's SWOT analysis: obesity program drives stock outlook - Investing.com
How Much Would It Take To Earn $100 A Month From Amgen Stock - Yahoo Finance
Amgen's (NASDAQ:AMGN) investors will be pleased with their favorable 34% return over the last three years - Simply Wall St
Amgen's (NASDAQ:AMGN) Dividend Will Be Increased To $2.38 - Simply Wall St
Amgen Inc. (NASDAQ:AMGN) Shares Bought by Franklin Resources Inc. - MarketBeat
World Investment Advisors LLC Raises Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dow's 112-point fall led by losses in NVIDIA Corp., Amgen shares - MarketWatch
Amgen to build $1B North Carolina pharmaceutical plant - Manufacturing Dive
Asset Advisors Investment Management LLC Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Synovus Financial Corp - MarketBeat
Virtu Financial LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ten Years of BLINCYTO® (blinatumomab): Celebrating the History, Impact and Future - Amgen
Wilmington Savings Fund Society FSB Grows Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Tudor Financial Inc. Purchases New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Morse Asset Management Inc Invests $806,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Why Amgen Inc. (AMGN) Is the Best Safe Stock to Buy According to Analysts? - Insider Monkey
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Invst LLC - MarketBeat
Toronto Dominion Bank Sells 40,188 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Amgen plans $1B investment in Holly Springs - Rocky Mount Telegram
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Amgen's Nobel Laureate Network: A Catalyst for Innovation - Marketscreener.com
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.29%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):